相关实验视频
Updated: Jan 10, 2026

07:34
Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies
Published on: April 11, 2012
20.0K
血胆固醇升高通过促进肝脏代谢重编程来改善败血症的结果
bioRxiv : the preprint server for biology
|November 24, 2025
概括
升高的胆固醇水平通过增强肝脏代谢来改善败血症的生存率. 这项研究揭示了因果关系,建议将向肝脏能量生产作为新的败血症治疗策略.
科学领域:
- 生物化学 生化学
- 病理生理学 病理生理学
- 基因组学就是基因组学.
背景情况:
- 败血症是一种危及生命的疾病,死亡率高,治疗选择有限.
- 低胆固醇水平 (低胆固醇血症) 与败血症的不良结果有关,但因果作用和机制尚不清楚.
研究的目的:
- 为了研究高血胆固醇是否能改善败血症的生存率.
- 确定胆固醇对败血症结果的影响的机制基础.
主要方法:
- 来自MIMIC-IV数据库的败血病患者数据的分析,比较幸存者和非幸存者之间的胆固醇水平.
- 考克斯回归来评估胆固醇与死亡率之间的关联,调整为共变量.
- 在被食高胆固醇饮食 (HCD) 或常规饮食 (RD) 的小鼠中,以诱导败血症并评估存活率.
主要成果:
- 幸存下来的败血症患者的胆固醇水平明显高于非幸存者.
- 高胆固醇 (≥133 mg/dL) 独立地与28天死亡率降低20%有关.
- 在小鼠中,HCD显著提高了败血症存活率,从52.5%提高到90%,并诱导肝脏代谢重编程,包括增强氧化酸化和抗氧化途径.
结论:
- 血胆固醇升高通过肝脏代谢重编程因果改善败血症结果.
- 这些发现为临床观察提供了机理性的洞察力,并强调肝脏生物能学作为毒症的潜在治疗标.
相关概念视频
Cholesterol: Significance and Regulation
1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.2K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
204
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Chronic Pancreatitis II: Collaborative Care
296
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
296
Atherosclerosis III: Management
301
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301

